Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2025 | $85.00 → $65.00 | Outperform → Strong Buy | Raymond James |
| 9/6/2024 | $57.00 → $79.00 | Equal Weight → Overweight | Barclays |
| 3/6/2024 | $48.00 | Equal Weight | Barclays |
| 8/31/2023 | $40.00 | Buy | Truist |
| 3/31/2023 | $30.00 | Market Outperform | CJS Securities |
| 3/3/2023 | $30.00 | Mkt Perform → Outperform | Raymond James |
| 8/12/2021 | Outperform → Market Perform | Raymond James | |
| 8/12/2021 | $39.00 | Overweight | Barclays |
EFFECT - RadNet, Inc. (0000790526) (Filer)
424B3 - RadNet, Inc. (0000790526) (Filer)
S-4/A - RadNet, Inc. (0000790526) (Filer)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
See-Mode's commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet's DeepHealth population health solutionsReal-world deployment of See-Mode's FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI innovation in ultrasound LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions through its wholly-owned subsidi
First quarter Revenue was negatively impacted by approximately $22 million and Adjusted EBITDA(1) was negatively impacted by approximately $15 million as a result of the Southern California wildfires and severe winter weather conditionsTotal Company Revenue increased 9.2% to $471.4 million in the first quarter of 2025 from $431.7 million in the first quarter of 2024Revenue from the Digital Health reportable segment increased 31.1% to $19.2 million in the first quarter of 2025 from $14.7 million in the first quarter of 2024Aggregate procedural volumes increased 3.6% and same-center procedural volumes decreased 0.3% compared with the first quarter of 2024Total Company Adjusted EBITDA(1) was $4
LOS ANGELES, May 09, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Bank of America Securities 2025 Healthcare Conference in Las Vegas, NV on Tuesday, May 13, 2025 at 5:00 p.m. Pacific Time. There will be simultaneous and archived webcasts available at https://bofa.veracast.com/webcasts/bofa/healthcare2025/id0NMyx8.cfm Details for RadNet's Presentation: Date:Tuesday, May 13, 2025Time:5:00 p.m. Pacific TimeLocat
Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo
See-Mode's commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet's DeepHealth population health solutionsReal-world deployment of See-Mode's FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI innovation in ultrasound LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions through its wholly-owned subsidi
First quarter Revenue was negatively impacted by approximately $22 million and Adjusted EBITDA(1) was negatively impacted by approximately $15 million as a result of the Southern California wildfires and severe winter weather conditionsTotal Company Revenue increased 9.2% to $471.4 million in the first quarter of 2025 from $431.7 million in the first quarter of 2024Revenue from the Digital Health reportable segment increased 31.1% to $19.2 million in the first quarter of 2025 from $14.7 million in the first quarter of 2024Aggregate procedural volumes increased 3.6% and same-center procedural volumes decreased 0.3% compared with the first quarter of 2024Total Company Adjusted EBITDA(1) was $4
LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2025 financial results on Monday, May 12, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1717619&tp_key=f0980d090d. An archived r
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously
Barclays upgraded RadNet from Equal Weight to Overweight and set a new price target of $79.00 from $57.00 previously
Barclays initiated coverage of RadNet with a rating of Equal Weight and set a new price target of $48.00